U.S. markets closed
  • S&P 500

    4,221.86
    -1.84 (-0.04%)
     
  • Dow 30

    33,823.45
    -210.22 (-0.62%)
     
  • Nasdaq

    14,161.35
    +121.67 (+0.87%)
     
  • Russell 2000

    2,287.46
    -27.23 (-1.18%)
     
  • Crude Oil

    71.06
    -1.09 (-1.51%)
     
  • Gold

    1,774.30
    -87.10 (-4.68%)
     
  • Silver

    25.95
    -1.86 (-6.69%)
     
  • EUR/USD

    1.1910
    -0.0090 (-0.75%)
     
  • 10-Yr Bond

    1.5110
    -0.0580 (-3.70%)
     
  • GBP/USD

    1.3919
    -0.0067 (-0.48%)
     
  • USD/JPY

    110.2040
    -0.4090 (-0.37%)
     
  • BTC-USD

    37,660.65
    -907.68 (-2.35%)
     
  • CMC Crypto 200

    934.98
    -34.90 (-3.60%)
     
  • FTSE 100

    7,153.43
    -31.52 (-0.44%)
     
  • Nikkei 225

    29,018.33
    -272.68 (-0.93%)
     

Insights on the $87+ Billion Cardiovascular Drugs Global Market to 2030 - Identify Growth Segments for Investment

·8 min read

Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Cardiovascular Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs market as it emerges from the COVID-19 shut down.

The global cardiovascular drugs market is expected to grow from $87.79 billion in 2020 to $92.41 billion in 2021 at a compound annual growth rate (CAGR) of 5.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $107.77 billion in 2025 at a CAGR of 4%.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.

  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

  • Create regional and country strategies on the basis of local data and analysis.

  • Identify growth segments for investment.

  • Outperform competitors using forecast data and the drivers and trends shaping the market.

  • Understand customers based on the latest market research findings.

  • Benchmark performance against key competitors.

  • Utilize the relationships between key data sets for superior strategizing.

  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cardiovascular Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider cardiovascular drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.

  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.

  • Market segmentations break down market into sub markets.

  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.

  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

  • The cardiovascular drugs market section of the report gives context. It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, cardiovascular drugs indicators comparison.

Major companies in the cardiovascular drugs market include Merck & Co; Sanofi S.A; Pfizer Inc; Bristol-Myers Squibb Company and Novartis AG.

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The cardiovascular drugs market is segmented into anti-hypertensive drugs; hypolipidemics; anti thrombotics; and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs).

Asia Pacific was the largest region in the global cardiovascular drugs market, accounting for 40% of the market in 2020. North America was the second largest region accounting for 27% of the global cardiovascular drugs market. Africa was the smallest region in the global cardiovascular drugs market.

NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.

High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs manufacturers.

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Cardiovascular Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Cardiovascular Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Cardiovascular Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Cardiovascular Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Cardiovascular Drugs Market Trends and Strategies

8. Impact of COVID-19 on Cardiovascular Drugs

9. Cardiovascular Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.3. Forecast Market Growth, Value ($ Billion)

10. Cardiovascular Drugs Market Regional Analysis
10.1. Global Cardiovascular Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Cardiovascular Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Cardiovascular Drugs Market, Growth and Market Share Comparison, by Region

11. Cardiovascular Drugs Market Segmentation
11.1. Global Cardiovascular Drugs Market, Segmentation by Type,
11.2. Global Cardiovascular Drugs Market, Segmentation by Distribution Channel
11.3. Global Cardiovascular Drugs Market, Segmentation by Route of Administration
11.4. Global Cardiovascular Drugs Market, Segmentation by Drug Classification
11.5. Global Cardiovascular Drugs Market, Segmentation by Mode of Purchase

12. Cardiovascular Drugs Market Metrics
12.1. Cardiovascular Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Cardiovascular Drugs Market Expenditure, 2015-2025, Global

13. Asia-Pacific Cardiovascular Drugs Market

14. Western Europe Cardiovascular Drugs Market

15. Eastern Europe Cardiovascular Drugs Market

16. North America Cardiovascular Drugs Market

17. South America Cardiovascular Drugs Market

18. Middle East Cardiovascular Drugs Market

19. Africa Cardiovascular Drugs Market

20. Cardiovascular Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. Merck & Co
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. Sanofi S.A
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. Pfizer Inc
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Bristol-Myers Squibb Company
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Novartis AG
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance

21. Key Mergers and Acquisitions in the Cardiovascular Drugs Market

22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)

23. Recommendations
23.1. Global Cardiovascular Drugs Market in 2025 - Growth Countries
23.2. Global Cardiovascular Drugs Market in 2025 - Growth Segments
23.3. Global Cardiovascular Drugs Market in 2025 - Growth Strategies

24. Appendix

25. Copyright and Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/348wib

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900